Response: Mutations of JAK2, JAK3 and GATA1 in acute megakaryoblastic leukemia of Down syndrome

Blood

Volumn 111, Issue 4, 2008, Pages 2493-2494

  Hama, Asahito ^b   Yagasaki, Hiroshi ^b   Takahashi, Yoshiyuki ^b   Matsumoto, Kimikazu ^b   Kiyoi, Hitoshi ^b   Kojima, Seiji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JANUS KINASE 3; TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DOWN SYNDROME; EXOPHTHALMOS; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LETTER; PRIORITY JOURNAL;

EID: 41349111082     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-10-117614     Document Type: Letter

References (9)

1. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19:1355-1360.
2. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102:2960-2968.
3. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
4. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10:65-75.
5. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia. 2007;21:574-576.
6. De Vita S, Mulligan C, McElwaine S, et al. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. Br J Haematol. 2007;137:337-341.
7. Norton A, Fisher C, Liu H, et al. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 2007;110:1077-1079.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
9. Park MJ, Shimada A, Asada H, Koike K, Tsuchida M, Hayashi Y. JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic Disorders. Leukemia. 2006;20:1453-1454.